Skip to content
Menu

Standard BioTools Inc. LAB

Full chart Compare
Set alert

Price alert · LAB

All alert types
0.61 USD +0.04 (+7.67%)

Regular-session close

0.63 +0.02 +2.97%

After hours · Nov 19, 6:30 PM ET

0.562 Day range 0.6302
0.39 52-week range 1.72
YTD
-52.05%
1 year
-52.05%

5D -0.0453 (-6.87%)

0.50000.60000.7000FriMonTueWedThu0.6137
Market cap
242.28M
Revenue (ttm)
155.90M
Profit margin
-79.92%
EPS (ttm)
-0.09
Shares out
372.26M
Forward P/E
-8.50
YTD return
-52.05%
1-year return
-52.05%
Volume
909.01K
Avg volume
1.19M
Open
0.562
Previous close
0.57
Day's range
0.562 – 0.6302
52-week range
0.39 – 1.72
Beta
1.57
Price target
3.08 (+402.4%)

Key statistics

50-day average
1.87
200-day average
2.14
Enterprise value
236.50M
Price / sales
4.47
Price / book
1.52
Revenue growth
-14.20%
Free cash flow
-66.16M
Total cash
28.45M
Total debt
111.65M
Return on equity
-37.25%
Short % of float
7.59%

Fundamental scorecard

10 of 25 checks passed on LAB’s reported financials

ValueGrowthProfitabilityHealthDividend

10of 25 checks passed

  • Value 2 of 5
  • Growth 1 of 5
  • Profitability 3 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
LAB Revenue — quarterly 19.39M
LAB Net income — quarterly 13.48M
LAB EPS — quarterly 0.03

Earnings

LAB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Oct 30, 2024Sep 1, 2024-0.08-0.05+0.03+37.50%
Jul 31, 2024Jun 1, 2024-0.06-0.08-0.02-33.33%
May 8, 2024Mar 1, 2024-0.09-0.23-0.14-155.56%
Feb 28, 2024Dec 1, 2023-0.13-0.08+0.05+38.46%
Nov 7, 2023Sep 1, 20230.00-0.15——
Aug 8, 2023Jun 1, 20230.00-0.14——

Upgrades / downgrades

LAB analyst upgrades and downgrades
DateFirmActionFromTo
Oct 31, 2024TD CowenmainBuyBuy
Aug 1, 2024TD CowenmainBuyBuy
Apr 16, 2024TD Coweninit—Buy
Apr 4, 2024Jefferiesinit—Buy
Jul 12, 2023Keybancinit—Overweight

About Standard BioTools Inc.

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on LAB — it syncs with the Stock Master app.

Insider holders

LAB insider holders
InsiderRelationLatest transactionDateShares held
BLACK JEFFREY GChief Financial OfficerConversion of Exercise of derivative securityAug 14, 2024428,298
CAREY THOMAS DDirectorStock Award(Grant)Jun 27, 202443,128
CASDIN ELIDirector and Beneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Jul 18, 202466,730,900
CASDIN PARTNERS MASTER FUND, L.P.Director and Beneficial Owner of more than 10% of a Class of SecurityPurchaseAug 26, 20240
COX TROY MDirectorStock Award(Grant)Jun 27, 2024161,820
EGHOLM MICHAELChief Executive OfficerStock Award(Grant)May 19, 20241,531,590

Institution ownership

LAB institution ownership
Holder% heldSharesValueReported
Casdin Capital, LLC19.14%71,254,677133.25MSep 29, 2024
Viking Global Investors, L.P.15.76%58,651,170109.68MSep 29, 2024
Blackrock Inc.6.03%22,452,11541.99MSep 29, 2024
Vanguard Group Inc4.65%17,292,09232.34MSep 29, 2024
Morgan Stanley4.10%15,245,46128.51MSep 29, 2024
Sumitomo Mitsui Trust Holdings, Inc.2.57%9,578,56317.91MSep 29, 2024

Fund ownership

LAB fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.49%9,268,38017.33MSep 29, 2024
iShares Russell 2000 ETF2.03%7,569,23814.15MOct 30, 2024
ARK ETF Tr-ARK Genomic Revolution ETF1.87%6,975,60513.04MOct 30, 2024
Vanguard Extended Market Index Fund1.28%4,775,0668.93MSep 29, 2024
Morgan Stanley Inst Fund Inc-Inception Port0.95%3,549,8786.64MSep 29, 2024
Fidelity Small Cap Index Fund0.83%3,087,3145.77MAug 30, 2024